NEWS HIGHLIGHTSMedia Articles Related to Ovide (Malathion Topical)
BIO Announces Presidents Bill Clinton And George W. Bush To Provide Keynote At 2010 BIO International Convention
Source: Health News from Medical News Today [2009.11.19]
The Biotechnology Industry Organization (BIO) announces that Presidents Bill Clinton and George W. Bush, the 42nd and 43rd Presidents of the United States, will appear together for a moderated discussion at the 2010 BIO International Convention, which will be held May 3-6 in Chicago, Ill. at McCormick Place.
Sangamo BioSciences Provides Update On Phase 1 Safety Trial Of SB-728-T For HIV/AIDS
Source: Clinical Trials / Drug Trials News From Medical News Today [2009.11.19]
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were inadvertently and prematurely disclosed on the internet.
Petascale Computing Tools Could Provide Deeper Insight Into Genomic Evolution
Source: Biology / Biochemistry News From Medical News Today [2009.11.18]
Technological advances in high-throughput DNA sequencing have opened up the possibility of determining how living things are related by analyzing the ways in which their genes have been rearranged on chromosomes. However, inferring such evolutionary relationships from rearrangement events is computationally intensive on even the most advanced computing systems available today.
Mersana Therapeutics Provides Clinical Update From Ongoing Phase 1 Study Of XMT-1001 In Patients With Advanced Solid Tumors
Source: Cancer / Oncology News From Medical News Today [2009.11.18]
Mersana Therapeutics, a platform-based cancer therapeutics company, announced additional preliminary results from an ongoing Phase 1 study of its lead development candidate, XMT-1001, in patients with advanced solid tumors. The results were presented in a poster session at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in Boston, MA November 15-19, 2009.
Previous Seasonal Flu Infections May Provide Some Level Of H1N1 Immunity
Source: Flu / Cold / SARS News From Medical News Today [2009.11.18]
Researchers at the La Jolla Institute for Allergy & Immunology have found that previous influenza infections may provide at least some level of immunity to the H1N1 "swine" flu. "The question we asked was, "Is the swine flu more like the seasonal flu or like a totally new strain of influenza where there would be no immunity?," said Alessandro Sette, Ph.D., an internationally recognized vaccine expert and director of the La Jolla Institute's Center for Infectious Disease.
Published Studies Related to Ovide (Malathion Topical)
Randomised, controlled, assessor blind trial comparing 4% dimeticone lotion with 0.5% malathion liquid for head louse infestation. [2007.11.07]
BACKGROUND: Malathion 0.5% has been the most prescribed pediculicide in the United Kingdom for around 10 years, and is widely used in Europe and North America...
Efficacy of a reduced application time of Ovide lotion (0.5% malathion) compared to Nix creme rinse (1% permethrin) for the treatment of head lice. [2004.11]
Our objective was to conduct a randomized, investigator-blinded evaluation of the pediculicidal and ovicidal activity of a reduced application time (20 minutes) of Ovide (0.5% malathion) compared to Nix (1% permethrin) in a south Florida population infested with Pediculus humanus capitis...
A randomized, investigator-blinded, time-ranging study of the comparative efficacy of 0.5% malathion gel versus Ovide Lotion (0.5% malathion) or Nix Creme Rinse (1% permethrin) used as labeled, for the treatment of head lice. [2007.07]
One hundred seventy-two subjects with head lice participated in a five-way, investigator-blinded, parallel-group, active-controlled study comparing 0.5% malathion gel (30, 60, and 90 minutes applications), Ovide Lotion (0.5% malathion), and Nix Creme Rinse (1% permethrin)... In conclusion, the 30-minute malathion gel, which contains the same ingredients and concentrations as Ovide, provides comparable efficacy, offers increased safety and is more cosmetically acceptable than Ovide.
Survey of permethrin and malathion resistance in human head lice populations from Denmark. [2006.05]
Head lice, Pediculis capitis De Geer, populations were investigated for permethrin and malathion resistance after initial establishment of a discriminating dose of topical application bioassay with body lice, Pediculus humanus L. For both insecticides, approximately 2 times the lethal dose (LD)95 at 4 h was selected, 2 ng of permethrin and 100 ng of malathion per head louse, respectively...
Decreasing malathion application time for lice treatment reduces transdermal absorption. [2005.09.14]
OBJECTIVE: Head lice are the most common parasitic infestation in the United States requiring topical treatment with pediculicides. Ovide, the 0.5% malathion formulation used in treatment of head lice requires placement on dry hair for 8-12 h. Malathion, however, is effective at killing lice and nits in 10 min. Our concern of over exposing children to malathion has led us to examine whether significantly more malathion will penetrate transdermally when applied for the recommended 8 h than for a shorter but apparently equally effective period... CONCLUSIONS: Significantly less malathion penetrated from Ovide after 0.5 h versus the suggested 8 h application, without decreasing the product's efficacy. Further clinical studies in children are warranted to confirm the efficacy of this shortened application time.
Clinical Trials Related to Ovide (Malathion Topical)
Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice [Completed]
Current treatments for head lice include over-the-counter products such as permethrin and
prescription products such as OVIDE (malathion 0. 5%) lotion. In a previous phase II study, a
novel, easy-to-use malathion 0. 5% formulation was found to be a safe treatment for head lice.
The current study will compare the efficacy and safety of this novel formulation of
malathion with OVIDE and with an over-the-counter permethrin product.
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice [Recruiting]
In this study, Malathion Gel 0. 5% will be compared to Nix (permethrin 1%) as a treatment for
head lice in patients 2 years of age and older. Malathion Gel 0. 5% is a new formulation of
an established head lice treatment. The new formulation has been evaluated in 2 previous
studies of patients 2 years of age and older.
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice [Recruiting]
In this study, Malathion Gel 0. 5% will be compared to Nix (permethrin 1%) as a treatment for
head lice in patients 2 years of age and older. Malathion Gel 0. 5% is a new formulation of
an established head lice treatment. The new formulation has been evaluated in 2 previous
studies of patients 2 years of age and older.
Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice [Recruiting]
In a previous phase II study, the safety and efficacy of a novel formulation of malathion
0. 5% was evaluated in patients 2 years of age and older. Based on the results of that study,
this formulation is currently in a phase III study for that population.
The current study will use blood markers and clinical evaluations to determine the safety
and tolerability of this formulation when used in children 6-24 months of age.
Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice [Terminated]
In a previous phase II study, the safety and efficacy of a novel formulation of malathion
0. 5% was evaluated in patients 2 years of age and older. Based on the results of that study,
this formulation is currently in a phase III study for that population.
The current study will use blood markers and clinical evaluations to determine the safety and
tolerability of this formulation when used in children 6-24 months of age.
|
